Loading…
Enlivex Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.5% over 5Y.
today you would have $4.03▼ -99.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $10.55 | $17.55 | $40.50 | $59.07 | $93.75 | $126.45 | $125.86 | $92.88 | $274.32 | $624.00 | $2,322.00 | $3,834.00 | |
| P/E | — | 0.0x | — | — | — | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BFRIBiofrontera Inc. | $1.59 | — | 3.8x | — | -988.35% | $23.62M |
| NXTCNextCure, Inc. | $5.18 | — | 1.7x | — | -204.56% | $23.71M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |
| JSPRJasper Therapeutics, Inc. | $0.70 |
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| P/B | 2.0x | 0.1x | 1.2x | 1.7x | 1.3x | 1.3x | 3.5x | 7.7x | 2.2x | 0.9x | 6.1x | 3.1x | 3.0x |
| EPS | $382.20 | -$10.95 | -$23.40 | -$25.35 | -$12.15 | -$13.50 | -$16.65 | -$21.00 | -$14.10 | -$601.95 | -$648.00 | -$342.00 |
| ROE | -49.17% | 63.85% | -63.65% | -96.62% | -54.64% | -17.01% | -33.32% | -83.18% | -43.70% | -29.48% | -570.18% | -85.68% | -22.89% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 14.0x |
| — |
| -255.04% |
| $23.28M |
| CNSYCerenome Inc | $3.05 | 1.1x | 4.1x | — | -614.05% | $23.15M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |